Are there data comparing Glivec with IFN-α?
• The large phase 3 randomised IRIS trial provides data to support that Glivec therapy for chronic-phase CML patients has superior efficacy compared with IFN-α + Ara-C, the previous standard of care in newly diagnosed chronic phase patients with CML81. Glivec is well tolerated, with most adverse events being mild to moderate in severity. • Glivec has also demonstrated efficacy in patients who are refractory or intolerant to IFN-α4. • Data from a historical comparison between 2 phase 3 trials demonstrate that there is a significant survival advantage (P 80.
